| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
MHI-148 targets tumor cells, demonstrating preferential accumulation in the lysosomes and mitochondria of tumor cells but not in normal cells. The compound does not target a specific protein or enzyme but rather exhibits tumor-selective uptake through mechanisms that are not fully elucidated, potentially involving organic anion transporting polypeptides (OATPs) overexpressed in cancer cells.
|
|---|---|
| ln Vitro |
MHI-148 (10 µM, 1 h) has tumor imaging and targeting properties and is absorbed much higher in HT-29 colon cancer cells than in normal NIH3T3 fibroblasts[1]. In HT-29 and NIH3T3 cells, MHI-148 (0-1.5 µM, 3 days) only slightly damages the cells[1].
The in vitro activity of MHI-148 is its function as a tumor-targeting near-infrared fluorescent probe. The compound exhibits strong NIR fluorescence and is taken up by tumor cells, accumulating in lysosomes and mitochondria. At 10 µM, MHI-148 demonstrates cellular uptake and fluorescence in cancer cells. The compound enables the visualization of tumors and can be used for diagnostic imaging and research applications. |
| ln Vivo |
MHI-148 has demonstrated in vivo tumor-targeting properties. The compound is taken up by and accumulates in tumors in animal models, allowing for NIR fluorescence imaging of cancer. MHI-148 can be used for cancer detection, diagnosis, and research. Upon application of NIR 808 nm laser, the compound can trigger on-demand drug release.
|
| Enzyme Assay |
In vitro binding assays are not applicable for MHI-148 as it functions as a tumor-targeting fluorescent dye rather than a drug targeting specific enzymes or receptors. The compound's interaction with tumor cells is based on its preferential uptake and accumulation in cancer cells.
|
| Cell Assay |
For in vitro cellular experiments, MHI-148 is dissolved in DMSO and diluted in cell culture medium. Tumor cells and normal cells are incubated with the compound at appropriate concentrations. The uptake and accumulation of the dye in cells are analyzed by fluorescence microscopy or flow cytometry. Preferential accumulation in tumor cell lysosomes and mitochondria can be assessed using organelle-specific counterstains.
|
| Animal Protocol |
For in vivo animal experiments, MHI-148 is administered to tumor-bearing mouse models. The compound is taken up by and accumulates in tumors, allowing for NIR fluorescence imaging. The dye enables the detection, diagnosis, and study of cancer in vivo. Upon application of NIR 808 nm laser, the compound can trigger on-demand drug release, making it useful for photothermal therapy and drug delivery applications.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MHI-148 have not been extensively characterized. The compound has a molecular weight of 764.23 g/mol and should be stored under appropriate conditions, protected from light.
|
| Toxicity/Toxicokinetics |
The compound is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References | |
| Additional Infomation |
MHI-148 (IR808) is a tumor-targeting near-infrared heptamethine cyanine dye for cancer detection, diagnosis, and research. It preferentially accumulates in tumor cell lysosomes and mitochondria and can trigger on-demand drug release upon NIR laser application. The compound has no clinical or therapeutic applications and has not received regulatory approval.
|
| Molecular Formula |
C42H52BRCLN2O4
|
|---|---|
| Molecular Weight |
764.230290412903
|
| Exact Mass |
762.279
|
| CAS # |
172971-76-5
|
| PubChem CID |
45100707
|
| Appearance |
Light green to green solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
50
|
| Complexity |
1270
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N1C(C(C)(C)C2=CC=CC=C12)=CC=C1CCCC(C=CC2C(C3=CC=CC=C3[N+]=2CCCCCC(=O)O)(C)C)=C1Cl)CCCCC(=O)O.[Br-]
|
| InChi Key |
SBSLCJXMLMGYFH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C42H51ClN2O4.BrH/c1-41(2)32-18-9-11-20-34(32)44(28-13-5-7-22-38(46)47)36(41)26-24-30-16-15-17-31(40(30)43)25-27-37-42(3,4)33-19-10-12-21-35(33)45(37)29-14-6-8-23-39(48)49;/h9-12,18-21,24-27H,5-8,13-17,22-23,28-29H2,1-4H3,(H-,46,47,48,49);1H
|
| Chemical Name |
6-[(2E)-2-[(2E)-2-[3-[(E)-2-[1-(5-carboxypentyl)-3,3-dimethylindol-1-ium-2-yl]ethenyl]-2-chlorocyclohex-2-en-1-ylidene]ethylidene]-3,3-dimethylindol-1-yl]hexanoic acid;bromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 20.83 mg/mL (27.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (1.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (1.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3085 mL | 6.5425 mL | 13.0851 mL | |
| 5 mM | 0.2617 mL | 1.3085 mL | 2.6170 mL | |
| 10 mM | 0.1309 mL | 0.6543 mL | 1.3085 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
